BD (Becton Dickinson & Company)

BD is a large, diverse, global medical technology company. Its Medical-Pharmaceutical Systems division is the world’s largest syringe manufacturer. It offers prefillable syringes, self-injection systems, safety and shielding solutions, and needle technologies and associated pharma services.

Worldwide Headquarters
Becton Dickinson - Franklin Lakes Campus
1 Becton Drive
Franklin Lakes
New Jersey
United States

Phone / Contact

T: +1 201 847 6800

Connect

The BD Medical-Pharmaceutical Systems division of BD is the world’s largest syringe manufacturer. It offers prefillable syringes, self-injection systems, safety and shielding solutions, and needle technologies and associated pharma services. It has expertise in drug container interactions, primary container selection and container/device integration for a variety of drug therapies.

BD is a large, diverse, global medical technology company that provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures and support the management of diabetes. The company has more than 40,000 employees across 190 countries.

Articles by BD (Becton Dickinson & Company)

Beth McBride DiLauri

BD INNOVATION FOR SUBCUTANEOUS DELIVERY OF LARGE-VOLUME COMPLEX BIOLOGICS

Beth McBride DiLauri summarises the results of a clinical study on the BD Libertas™ Wearable Injector. The results position the device as a viable alternative to traditional intravenous administration.

INDUSTRIALISATION

RFID-BASED UNIT-LEVEL TRACEABILITY: COULD IT BE THE KEY TO OPERATIONAL EXCELLENCE FOR FILL-FINISH LINES?

Yacine Haddadi and Herve Soukiassian look at how the company’s track & trace model can help manufacturers improve their fill-finish operations.

A PATIENT-CENTRIC, CONNECTED INJECTION DEVICE FOR DECENTRALISED CLINICAL TRIALS – THE HUMAN FACTORS RESULTS ARE IN!

Aurélie Pager and Mircea Despa follow up on an article published in the December 2021 issue of ONdrugDelivery. BD has now completed a human factors study assessing the usability, acceptance and ease of use of its connected injection prototype for clinical trials.

PREFILLED SYRINGES

NEW BD SCF™ PREMIUMCOAT^® 1MLL PLUNGER STOPPER: GLIDING TOWARDS DE-RISKED COMBINATION PRODUCT DEVELOPMENT

Victoria Meyer introduces the BD SCF™ PremiumCoat^® 1mlL Plunger Stopper and explains how the product’s role is critical in determining combination products’ exposure to extractables and leachables.

TRIALS WITHOUT TRIBULATIONS: A PATIENT-CENTRIC, CONNECTED INJECTION DEVICE FOR DECENTRALISED AND HYBRID CLINICAL TRIALS

Rebecca Beck and Hervé Monchoix discuss how stakeholder needs are driving the development of a new, connected injection device from BD, to support decentralised and hybrid clinical trials.

INDUSTRIALISATION

THE FUTURE OF CONTAINER-LEVEL TRACEABILITY FOR PREFILLABLE SYRINGES

Sam Eubanks and Hervé Soukiassian discuss the BD traceability solution. This concept under development aims to deliver traceability at the unique container level from manufacture to the point of care.

PREFILLED SYRINGES

Sophie Trémeau

BD HYLOK™ – GLASS PREFILLABLE SYRINGE FOR IV APPLICATIONS

Sophie Trémeau, Maxime Nicolas and Myriam Leszczynski discuss BD Hylok™, a prefillable glass syringe for intravenous applications, including the rigorous testing BD Hylok™ has undergone and the regulatory support BD is able to provide to its pharmaceutical partners.

INNOVATING IN THE VISCOSITY DESIGN SPACE: A NEW 2.25 ML AUTOINJECTOR PLATFORM

Karima Yadi and Lionel Maritan discuss BD’s response to the need for an autoinjector platform that reconciles the demands of biologics with safety, reliability and ease of use during self-injection: the Intevia™ 2.25 mL disposable autoinjector.

PREFILLED SYRINGES

Shorter Needles with Thinner Walls to Improve Injection Experience in Chronic Care

Aurélie Pager, Brigitte Duinat and Barbara Alves look at how new BD Neopak™ XtraFlow™ prefillable syringes with shorter, 8 mm needles and thinner-wall cannula technology are set to improve the injection experience for subcutaneous drug delivery in chronic care.

Dr Temitope Sodunke

ADDRESSING THE EVOLVING NEEDS OF VARIABLE DRUG DELIVERY REGIMENS

Temitope Sodunke introduces the BD Evolve™ On-body Injector and describes how the device is designed specifically to address the rapidly evolving needs of the pharma industry and meet patient requirements.

PREFILLED SYRINGES

8 MM NEEDLE – IMPROVING SUBCUTANEOUS CHRONIC DRUG DELIVERY

Aurelie Pager describes how reducing needle length can improve the risk profile of subcutaneous injections and can make injecting viscous formulations easier and quicker, and highlights BD’s development programme for an innovative shorter needle with ultra-thin walls for prefilled syringes.

CO-PACKAGED COMPONENTS IMPROVE PATIENT EXPERIENCE AND ENSURE CONSISTENT DRUG DELIVERY

Chris Franzese and Amy Rinaldi explore the challenges and benefits of co-packaging for manufacturers, healthcare workers and patients.

Beth McBride DiLauri

THE CHANGING DRUG DELIVERY PARADIGM

Beth DiLauri sets out the fundamental case for the adoption of wearable injectors, outlines the specific barriers they overcome and describes how the design and development of the BD Libertas™ wearable injector platform make it an attractive proposal for pharma companies.

Cecile Halte, BD

In this interview, Cécile Halté, Senior Program Manager, Acute Care Segment, for BD Medical – Pharmaceutical Systems. discusses validation studies of the BD Sterifill Advance™ plastic prefilled syringe, which is intended for use in the hospital setting by healthcare professionals either for manual bolus injections, or with infusion pumps.

Dr Mircea Despa

MIRCEA DESPA & DOUG McCLURE, BD

In this interview, Dr Despa and Mr McClure discuss BD’s approach to connecting devices in its portfolio to meet patient, pharma and other stakeholder requirements. Their discussion focuses in particular on safety and security, highlighting the connected wearable injector, BD Libertas™ with Smart Option, as an example.

SELECTING THE RIGHT PRIMARY CONTAINER FOR INJECTABLES IN ACUTE CARE

Alfred Harvey explains why it’s important to select the right primary container presentation – and what can happen if you get it wrong.

SAGAR BEJALWAR, BD MEDICAL – PHARMACEUTICAL SYSTEMS

Sagar Bejalwar discusses the product and clinician needs in delivering hyaluronic acid for cosmetic applications.

PREFILLED SYRINGES

DRUG-DEVICE CO-PACKING SOLUTIONS TO ENHANCE DIFFERENTIATION AND IMPROVE EXPERIENCE

Janice Adkins discusses the benefits that co-packing, the practice of providing drug preparation and delivery systems along with a medication, can bring to pharmaceutical manufacturers, clinicians and patients.

ALICE MADEN & LIONEL MARITAN, BD MEDICAL – PHARMACEUTICAL SYSTEMS

Alice Maden and Lionel Maritan discuss with detailed expert knowledge the benefits of using integrated systems for sophisticated drug device combination products with multiple device subsystems.

Dr Sundeep Kankanala

SUNDEEP KANKANALA, BD

Sundeep Kankanala discusses the challenges faced by today’s biopharmaceutical industry, in particular those posed by the need for large volumes and the issues caused by the use of silicone in prefilled syringes.

PREFILLED SYRINGES

Dr Karen Guerrero

THE INCREASING REQUIREMENTS FOR HUMAN FACTORS CONSIDERATIONS

Karen Guerrero outlines how human factors engineering, now an essential requirement for all new drug delivery combination product approvals, can represent a significant challenge and how BD can help streamline this aspect of the development process.

PREFILLED SYRINGES

Dr Theresa Bankston

THE VALUE OF A BD INTEGRATED SYSTEM FOR COMBINATION PRODUCTS

Theresa Bankston looks at the advantages of using an integrated system for drug-device combination products. As well as avoiding problems such as breakage and incompatibility, integrated products can offer solutions at every interface between the drug, container and delivery device and save significant amounts of time and money.

Dr Sundeep Kankanala

ADDRESSING EVOLVING HEALTHCARE NEEDS WITH DIGITAL HEALTH: CONNECTING DRUG DELIVERY

Sundeep Kankanala, Dave Icke and Chris Franzese explain how BD is moving towards providing solutions rather than products, particularly in the field of diabetes, discussing two frameworks created to improve the impact of the connected solutions.

PREFILLED SYRINGES

Christian Herget

BREAKING THE 1 ML BARRIER

Christian Herget and Vincent Herin, explores the evolution of innovative syringe-based combination products for the administration of biopharmaceutical drugs.

Top